<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227951</url>
  </required_header>
  <id_info>
    <org_study_id>2245CESC</org_study_id>
    <nct_id>NCT04227951</nct_id>
  </id_info>
  <brief_title>Gastrectomy With or Without Drainage (ADiGe)?</brief_title>
  <acronym>ADiGe</acronym>
  <official_title>A Randomised Multicentre Controlled Trial of Gastrectomy With or Without Prophylactic Abdominal Drainage. The Abdominal Drain in Gastrectomy Trial (ADiGe Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Integrata Verona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic use of anastomotic drain in upper gastrointestinal surgery has been questioned
      in the last 15 years but only small studies have been conducted. In 2015 a Cochrane meta
      analysis on four Randomized Controlled Trials (RCT) concluded that there was no convincing
      evidence to the routine drain placement in gastrectomy. Nevertheless the Authors evidenced
      the moderate/low methodological quality of the included studies and highlighted how 3 out of
      four came from Eastern countries. Despite the above mentioned limits, Enhanced Recovery After
      Surgery (ERAS) society published the guidelines for gastrectomy that strongly recommend, with
      high evidence level, to avoid routine use of drain in gastric surgery. After 2015 some other
      retrospective studies have been published, all with inconsistent results. Our objective is to
      perform a multicentre prospective trial in a large western cohort of patients to establish
      wether avoid routine use of anastomotic drain does not led to an increasing of postoperative
      invasive procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The leading surgeon and the patient will be blinded to the arm assigned until the end of the operation. No blinding is provided for the patient, care providers, or coordinating researcher after the operation. After the operation we thought that was unreliable to go ahead with participants blindness considering that one arm has an evident drain and the other arm has no drain. Considering that clinicians will need to check drain quality and remove the tube in treatment group we considered not possible to mask the care providers or investigators on this practice.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>30 day reoperation AND/OR additional drain placement</measure>
    <time_frame>30 days after the operation</time_frame>
    <description>Incidence of reoperation AND/OR percutaneous placement of an additional drain within postoperative day 30 (composite outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>90 days after the operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall morbidity</measure>
    <time_frame>30 days after the operation OR in hospital if hospitalization is longer than 30 days, up to 90 days of hospitalization</time_frame>
    <description>Complications are classified according to International consensus on a complications list after gastrectomy for cancer - Baiocchi et Al, Gastric Cancer, 2019 and stratified according to Clavien-Dindo classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>From the day of operation until discharge (home or other facilities) or death for any cause whichever came first, assessed up to 100 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drain related complications</measure>
    <time_frame>From the day of operation until drain removal up to 90 days after the operation</time_frame>
    <description>Only in Drain Group complications related to drain placement (e.g. bleeding from drain site) will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Drain</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants enrolled in this arm have an abdominal drain positioned at the end of the operation (any type, inserted from right flank with the tip close to the esophago-jejunal or Gastro-jejunal anastomosis and the duodenal stump). Drain will stay in place until postoperative day (POD) 4th (drain output and quality will be registered). If normal drain debt and patient have no abdominal complications that need reoperation and/or percutaneous drain placement until POD 4, a methylene-blue test is be performed (200 ml water + 5 ml blue orally, check drain after 60 minutes: negative test if no blu was seen in the drain). If negative-blue test drain can be removed according to centre preference (no strict POD defined); if positive-blue test complication will be treated according to centre preference. Only in this arm drain related complications are registered. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Drain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants enrolled in this arm do not have any abdominal drain placed at the end of the operation. Postoperative management (e.g. resume of oral intake, anastomosis integrity tests) is left to centre preference. Need for reoperation and/or percutaneous drain placement (primary outcome) are registered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Avoid drain placement</intervention_name>
    <description>In No Drain arm (experimental) no abdominal drain is placed at the end of the operation.</description>
    <arm_group_label>No Drain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drain placement</intervention_name>
    <description>In Drain arm (sham comparator) an abdominal drain is inserted in the abdomen from the right flank, passing below the liver (close to the duodenal stump) with the apex behind the esophago-jejunal (in total gastrectomy) or gastro-jejunal (in subtotal gastrectomy) anastomosis.</description>
    <arm_group_label>Drain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all consecutive patients that undergo total or subtotal gastrectomy with a curative
             intent, for histologically proven gastric cancer or esophago-gastric junction cancer
             Siewert type II or III, in surgical investigator centres from the beginning of the
             study until reaching the accrual number

          -  esophageal involvement &lt;= 2 cm

          -  patients undergoing upfront surgery or treated with a neoadjuvant/perioperative
             chemotherapy

          -  open, hybrid, laparoscopic or robotic approach

          -  all types of anastomosis (circular stapled, linear stapled, hand sewn)

        Exclusion Criteria:

          -  refuse to sign informed consent

          -  age &lt;18

          -  Heart failure New York Heart Association (NYHA) class IV

          -  severe liver disease (Child &gt;= 7)

          -  pregnancy

          -  metastatic disease

          -  emergency surgery

          -  palliative surgery

          -  operation different from total or subtotal oncological gastrectomies (e.g. pylorus
             preserving, proximal gastrectomy)

          -  lymphnodal dissection &lt;D1

          -  reconstruction different from Roux-en-Y or Billroth II

          -  multiple organ resections (except for cholecystectomy)

          -  gastric cancer with duodenal involvement

          -  intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni de Manzoni, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† degli studi di Verona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacopo Weindelmayer, Dr</last_name>
    <phone>00390458127769</phone>
    <email>Jacopo.weindelmayer@aovr.veneto.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentina Mengardo, Dr</last_name>
    <phone>00390458123063</phone>
    <email>Valentina.mengardo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Morgagni di Forl√¨ - Chirurgia generale</name>
      <address>
        <city>Forl√¨</city>
        <state>Forl√¨-Cesena</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Morgagni, MD</last_name>
      <email>p.morgagni@ausl.fo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria San Luigi Gonzaga- Chirurgia Generale</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Degiuli, Prof.</last_name>
      <email>dr.mauriziodegiuli@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico San Marco, GSD - Chirurgia Generale ed Oncologica</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi - Dipartimento di Chirurgia Generale</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale metropolitano Niguarda - Chirurgia generale oncologica e mini-invasiva</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Gualtierotti, MD</last_name>
      <email>monica_gualtierotti@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele - Chirurgia Gastroenterologica -</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Rosati, Prof.</last_name>
      <email>rosati.riccardo@hsr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Federico II di Napoli- Chirurgia Generale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Maria degli Angeli Pordenone- Chirurgia generale</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Borgo Trento - Chirurgia Generale ed Esofago Stomaco</name>
      <address>
        <city>Verona</city>
        <zip>37124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacopo Weindelmayer, MD</last_name>
      <phone>00390458127769</phone>
      <email>Jacopo.weindelmayer@aovr.veneto.it</email>
    </contact>
    <contact_backup>
      <last_name>Valentina Mengardo, MD</last_name>
      <phone>00390458123063</phone>
      <email>Valentina.mengardo@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Wang Z, Chen J, Su K, Dong Z. Abdominal drainage versus no drainage post-gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2015 May 11;(5):CD008788. doi: 10.1002/14651858.CD008788.pub3. Review.</citation>
    <PMID>25961741</PMID>
  </reference>
  <reference>
    <citation>Mortensen K, Nilsson M, Slim K, Sch√§fer M, Mariette C, Braga M, Carli F, Demartines N, Griffin SM, Lassen K; Enhanced Recovery After Surgery (ERAS¬Æ) Group. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS¬Æ) Society recommendations. Br J Surg. 2014 Sep;101(10):1209-29. doi: 10.1002/bjs.9582. Epub 2014 Jul 21.</citation>
    <PMID>25047143</PMID>
  </reference>
  <reference>
    <citation>Schots JPM, Luyer MDP, Nieuwenhuijzen GAP. Abdominal Drainage and Amylase Measurement for Detection of Leakage After Gastrectomy for Gastric Cancer. J Gastrointest Surg. 2018 Jul;22(7):1163-1170. doi: 10.1007/s11605-018-3789-7. Epub 2018 May 7.</citation>
    <PMID>29736661</PMID>
  </reference>
  <reference>
    <citation>Dann GC, Squires MH 3rd, Postlewait LM, Kooby DA, Poultsides GA, Weber SM, Bloomston M, Fields RC, Pawlik TM, Votanopoulos KI, Schmidt CR, Ejaz A, Acher AW, Worhunsky DJ, Saunders N, Swords DS, Jin LX, Cho CS, Winslow ER, Russell MC, Staley CA, Maithel SK, Cardona K. Value of Peritoneal Drain Placement After Total Gastrectomy for Gastric Adenocarcinoma: A Multi-institutional Analysis from the US Gastric Cancer Collaborative. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S888-97. doi: 10.1245/s10434-015-4636-7. Epub 2015 May 29.</citation>
    <PMID>26023037</PMID>
  </reference>
  <reference>
    <citation>Hirahara N, Matsubara T, Hayashi H, Takai K, Fujii Y, Tajima Y. Significance of prophylactic intra-abdominal drain placement after laparoscopic distal gastrectomy for gastric cancer. World J Surg Oncol. 2015 May 12;13:181. doi: 10.1186/s12957-015-0591-9.</citation>
    <PMID>25962503</PMID>
  </reference>
  <reference>
    <citation>Lee J, Choi YY, An JY, Seo SH, Kim DW, Seo YB, Nakagawa M, Li S, Cheong JH, Hyung WJ, Noh SH. Do All Patients Require Prophylactic Drainage After Gastrectomy for Gastric Cancer? The Experience of a High-Volume Center. Ann Surg Oncol. 2015 Nov;22(12):3929-37. doi: 10.1245/s10434-015-4521-4. Epub 2015 Apr 7.</citation>
    <PMID>25845430</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrectomy</keyword>
  <keyword>Drain</keyword>
  <keyword>Drainage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Still evaluating with the study group. Plan is to share all Individual Participant Data that will be collected.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

